PT - JOURNAL ARTICLE AU - Wong, Serre-Yu AU - Gold, Stephanie AU - Accorsi, Emma K. AU - Cowger, Tori L. AU - Wiseman, Dean AU - Navalurkar, Reema AU - Dixon, Rebekah AU - Helmus, Drew S. AU - , AU - Firpo-Betancourt, Adolfo AU - Mendu, Damodara Rao AU - Zolla-Pazner, Susan AU - Cadwell, Ken AU - Colombel, Jean-Frederic TI - Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics AID - 10.1101/2021.03.15.21253615 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.15.21253615 4099 - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253615.short 4100 - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253615.full AB - Patients with immune-mediated inflammatory diseases (IMIDs) and acquired and genetic immunodeficiencies receiving therapeutic infusions are considered high risk for SARS-CoV-2 infection. However, the seroprevalance in this group and the safety of routine administrations at outpatient infusion centers are unknown. To determine the infection rate and clinical-social factors related to SARS-CoV-2 in asymptomatic patients with IMIDs and immunodeficiencies receiving routine non-cancer therapeutic infusions, we conducted a seroprevalence study at our outpatient infusion center. We report the first prospective SARS-CoV-2 sero-surveillance of 444 IBD/IMID, immunodeficiency, and immune competent patients at an outpatient infusion center in the U.S. showing lower seroprevalence in patients compared with the general population and provide clinical and social characteristics associated with seroprevalence in this group. These data suggest that patients can safely continue infusions at outpatient centers.Competing Interest StatementKen Cadwell reported receiving research funding from Pfizer, Takeda, and Abbvie; has consulted for or received an honorarium from Puretech Health, Genentech, and Abbvie; and holds U.S. patent 10,722,600 and provisional patent 62/935,035. Jean-Frederic Colombel reported receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and holding stock options in Intestinal Biotech Development. Subcontract support: Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays (US provisional application no. 63/059,924). Mount Sinai has also founded a subsidiary, Kantaro Biosciences, to market a commercial version of the assay described in this manuscript. The remaining authors disclose no conflicts.Funding StatementThis work was supported by the Hemlsey Trust, Cure for IBD, T32AI007535 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The Mount Sinai Serological Sciences Network (SeroNet) is supported by Federal funds from the National Cancer Institute, National Institutes of Health, under contract no. 5N91019D00024, task order no. 75N91020F00003 and under U54 CA260560-01. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Mount Sinai School of Medicine reviewed and approved the SARS-CoV-2 exposure in patients with altered immune function study (IRB 20-03464).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis data will be shared upon request.